AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
PHASE-II TRIAL OF FIRST-LINE HIGH-DOSE IFOSFAMIDE IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - A STUDY OF THE SPANISH GROUP FOR RESEARCHON SARCOMAS (GEIS)
Authors: BUESA JM LOPEZPOUSA A MARTIN J ANTON A DELMURO JG BELLMUNT J ARRANZ F VALENTI V ESCUDERO P MENENDEZ D CASADO A POVEDA A
Citation: Jm. Buesa et al., PHASE-II TRIAL OF FIRST-LINE HIGH-DOSE IFOSFAMIDE IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT - A STUDY OF THE SPANISH GROUP FOR RESEARCHON SARCOMAS (GEIS), Annals of oncology, 9(8), 1998, pp. 871-876
PHASE-II STUDY OF VINORELBINE AND ESTRAMUSTINE PHOSPHATE IN HORMONE-RESISTANT CARCINOMA OF THE PROSTATE (HRPC) PRELIMINARY-RESULTS
Authors: CARLES J BASTUS R BROTO J NOGUE M TABERNERO J SALAZAR R ARCUSA A DOMENECH M BELLMUNT J GARCIA A ROMERO J TRESCA P
Citation: J. Carles et al., PHASE-II STUDY OF VINORELBINE AND ESTRAMUSTINE PHOSPHATE IN HORMONE-RESISTANT CARCINOMA OF THE PROSTATE (HRPC) PRELIMINARY-RESULTS, Annals of oncology, 9, 1998, pp. 286-286
2ND LINE CHEMOTHERAPY BASED IN VINORELBINE AND ORAL FLUOPIRIMIDINES IN RELAPSING HEAD AND NECK-CANCER - A PILOT-STUDY - OUTCOME AND SYMPTOMCONTROL
Authors: CARULLA J BELLMUNT J SANZ X SANCHEZ JM URDAMBIDELUS A GIRALT J DELCAMPO JM BODI R SOLECALVO LA
Citation: J. Carulla et al., 2ND LINE CHEMOTHERAPY BASED IN VINORELBINE AND ORAL FLUOPIRIMIDINES IN RELAPSING HEAD AND NECK-CANCER - A PILOT-STUDY - OUTCOME AND SYMPTOMCONTROL, Annals of oncology, 9, 1998, pp. 367-367
LETROZOLE, A NEW ORAL AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - DOUBLE-BLIND RANDOMIZED TRIAL SHOWING A DOSE-EFFECT AND IMPROVED EFFICACY AND TOLERABILITY COMPARED WITH MEGESTROL-ACETATE
Authors: DOMBERNOWSKY P SMITH I FALKSON G LEONARD R PANASCI L BELLMUNT J BEZWODA W GARDIN G GUDGEON A MORGAN M FORNASIERO A HOFFMANN W MICHEL J HATSCHEK T TJABBES T CHAUDRI HA HORNBERGER U TRUNET PF
Citation: P. Dombernowsky et al., LETROZOLE, A NEW ORAL AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - DOUBLE-BLIND RANDOMIZED TRIAL SHOWING A DOSE-EFFECT AND IMPROVED EFFICACY AND TOLERABILITY COMPARED WITH MEGESTROL-ACETATE, Journal of clinical oncology, 16(2), 1998, pp. 453-461
P53 ONCOPROTEIN AS A PROGNOSTIC INDICATOR IN PATIENTS WITH BREAST-CANCER
Authors: MOLINA R SEGUI MA CLIMENT MA BELLMUNT J ALBANELLI J FERNANDEZ M FILELLA X JO J GIMENEZ N IGLESIAS E MIRALLES M ALONSO C PEIRO G PEREZPICANOL E BALLESTA AM
Citation: R. Molina et al., P53 ONCOPROTEIN AS A PROGNOSTIC INDICATOR IN PATIENTS WITH BREAST-CANCER, Anticancer research, 18(1B), 1998, pp. 507-511
REGULATORY PROTEINS OF THE CELL-CYCLE - ALTERATIONS IN THE CYCLIN C1 ROUTE AS A PARADIGM - FINDINGS IN BREAST-CANCER
Authors: ERES N BELLMUNT J
Citation: N. Eres et J. Bellmunt, REGULATORY PROTEINS OF THE CELL-CYCLE - ALTERATIONS IN THE CYCLIN C1 ROUTE AS A PARADIGM - FINDINGS IN BREAST-CANCER, Medicina Clinica, 111(15), 1998, pp. 592-596
CYCLOPHOSPHAMIDE, METHOTREXATE, AND CHRONIC ORAL TEGAFUR MODULATED BYFOLINIC ACID IN THE TREATMENT OF PATIENTS WITH ADVANCED BREAST-CARCINOMA
Authors: RIBAS A ALBANELL J SOLECALVO LA GALLARDO E BELLMUNT J VERA R VIDAL R CARULLA J BASELGA J
Citation: A. Ribas et al., CYCLOPHOSPHAMIDE, METHOTREXATE, AND CHRONIC ORAL TEGAFUR MODULATED BYFOLINIC ACID IN THE TREATMENT OF PATIENTS WITH ADVANCED BREAST-CARCINOMA, Cancer, 82(5), 1998, pp. 878-885
ADVERSE EFFECT ON BONE-MARROW PROTECTION OF PRECHEMOTHERAPY GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT
Authors: RIBAS A ALBANELL J BELLMUNT J SOLECALVO LA
Citation: A. Ribas et al., ADVERSE EFFECT ON BONE-MARROW PROTECTION OF PRECHEMOTHERAPY GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT, Journal of the National Cancer Institute, 89(5), 1997, pp. 395-395
FREQUENT DOSE DELAYS AND GROWTH-FACTOR REQUIREMENTS WITH THE SEQUENTIAL DOXORUBICIN-CMF SCHEDULE
Authors: RIBAS A ALBANELL J BELLMUNT J BERMEJO B GALLARDO E VERA R BODI R SOLECALVO LA
Citation: A. Ribas et al., FREQUENT DOSE DELAYS AND GROWTH-FACTOR REQUIREMENTS WITH THE SEQUENTIAL DOXORUBICIN-CMF SCHEDULE, Acta oncologica, 36(7), 1997, pp. 701-704
PULMONARY METASTATIZING BENIGN LEIOMYOMA EVOLVING TO CHRONIC RESPIRATORY-FAILURE
Authors: SALUD A PORCEL JM VIDALPLA R BELLMUNT J
Citation: A. Salud et al., PULMONARY METASTATIZING BENIGN LEIOMYOMA EVOLVING TO CHRONIC RESPIRATORY-FAILURE, Medicina Clinica, 109(9), 1997, pp. 358-358
CARBOPLATIN-BASED VERSUS CISPLATIN-BASED CHEMOTHERAPY IN THE TREATMENT OF SURGICALLY INCURABLE ADVANCED BLADDER-CARCINOMA
Authors: BELLMUNT J RIBAS A ERES N ALBANELL J ALMANZA C BERMEJO B SOLE LA BASELGA J
Citation: J. Bellmunt et al., CARBOPLATIN-BASED VERSUS CISPLATIN-BASED CHEMOTHERAPY IN THE TREATMENT OF SURGICALLY INCURABLE ADVANCED BLADDER-CARCINOMA, Cancer, 80(10), 1997, pp. 1966-1972
5-DAY COURSE OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH PROLONGED NEUTROPENIA AFTER ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER IS A SAFE AND COST-EFFECTIVE SCHEDULE TO MAINTAIN DOSE-INTENSITY
Authors: RIBAS A ALBANELL J BELLMUNT J SOLECALVO LA BERMEJO B GALLARDO E VIDAL R VERA R ERES N CARULLA J BASELGA J
Citation: A. Ribas et al., 5-DAY COURSE OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH PROLONGED NEUTROPENIA AFTER ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER IS A SAFE AND COST-EFFECTIVE SCHEDULE TO MAINTAIN DOSE-INTENSITY, Journal of clinical oncology, 14(5), 1996, pp. 1573-1580
EARLY RESULTS OF THE VALUE OF P53 IN PREDICTING SURVIVAL IN A HOMOGENEOUS COHORT OF PATIENTS WITH INVASIVE BLADDER-CANCER TREATED WITH A NEOADJUVANT CARBOPLATIN-BASED REGIMEN (M-CAVI)
Authors: RIBAS A BELLMUNT J ALBANELL J DETORRES I BERMEJO B DETORRES JA MOROTE J GALLARDO E VERA R CARULLA J SOLECALVO LA
Citation: A. Ribas et al., EARLY RESULTS OF THE VALUE OF P53 IN PREDICTING SURVIVAL IN A HOMOGENEOUS COHORT OF PATIENTS WITH INVASIVE BLADDER-CANCER TREATED WITH A NEOADJUVANT CARBOPLATIN-BASED REGIMEN (M-CAVI), Tumori, 82(6), 1996, pp. 554-559
M-CAVI, A NEOADJUVANT CARBOPLATIN-BASED REGIMEN FOR THE TREATMENT OF T2-4NOMO CARCINOMA OF THE BLADDER
Authors: BELLMUNT J RIBAS A ALBANELL J BERMEJO B VERA R DETORRES JA MOROTE J LOPEZPACIOS MA MANUS JM ROVIROSA A CARULLA J SOLE LA
Citation: J. Bellmunt et al., M-CAVI, A NEOADJUVANT CARBOPLATIN-BASED REGIMEN FOR THE TREATMENT OF T2-4NOMO CARCINOMA OF THE BLADDER, American journal of clinical oncology, 19(4), 1996, pp. 344-348
THE CLINICAL IMPORTANCE OF THE FIBROBLAST GROWTH-FACTOR AS A BIOLOGICAL MARKER AND THERAPEUTIC MODULATOR - FUTURE APPLICATIONS
Authors: ERES N BELLMUNT J
Citation: N. Eres et J. Bellmunt, THE CLINICAL IMPORTANCE OF THE FIBROBLAST GROWTH-FACTOR AS A BIOLOGICAL MARKER AND THERAPEUTIC MODULATOR - FUTURE APPLICATIONS, Medicina Clinica, 107(8), 1996, pp. 296-298
ENDOBRONCHIAL METASTATIC DISEASE - ANALYSIS OF 32 CASES
Authors: SALUD A PORCEL JM ROVIROSA A BELLMUNT J
Citation: A. Salud et al., ENDOBRONCHIAL METASTATIC DISEASE - ANALYSIS OF 32 CASES, Journal of surgical oncology, 62(4), 1996, pp. 249-252
HIGH-DOSE CONTINUOUS-INFUSION (CI) IFOSFAMIDE WITHOUT HEMATOPOIETIC SUPPORT IN HEAVILY PRETREATED BREAST-CANCER (BC) AND SARCOMA (S) PATIENTS
Authors: BELLMUNT J RIBAS A CASADO S ALBANELL J CARULLA J SOLE LA
Citation: J. Bellmunt et al., HIGH-DOSE CONTINUOUS-INFUSION (CI) IFOSFAMIDE WITHOUT HEMATOPOIETIC SUPPORT IN HEAVILY PRETREATED BREAST-CANCER (BC) AND SARCOMA (S) PATIENTS, European journal of cancer, 31A, 1995, pp. 932-932
MULTIDRUG-RESISTANCE IN BLADDER-CANCER - ROLE OF P-GLYCOPROTEIN IN THE RESPONSE TO CHEMOTHERAPY
Authors: VICENTE P BELLMUNT J ARMADANS L DETORRES I JOLIS L
Citation: P. Vicente et al., MULTIDRUG-RESISTANCE IN BLADDER-CANCER - ROLE OF P-GLYCOPROTEIN IN THE RESPONSE TO CHEMOTHERAPY, European journal of cancer, 31A, 1995, pp. 1165-1165
TRANSDUCTION AND SELECTION OF MURINE TUMOR-CELLS ENGINEERED TO EXPRESS THE INTERLEUKIN-2 (IL-2) AND HERPES-SIMPLEX VIRUS THYMIDINE KINASE (HSVTK) GENES
Authors: RIBAS A FAKHRAI H SHAWLER D SOBOL R BELLMUNT J SOLE LA
Citation: A. Ribas et al., TRANSDUCTION AND SELECTION OF MURINE TUMOR-CELLS ENGINEERED TO EXPRESS THE INTERLEUKIN-2 (IL-2) AND HERPES-SIMPLEX VIRUS THYMIDINE KINASE (HSVTK) GENES, European journal of cancer, 31A, 1995, pp. 1277-1277
MALIGNANT LYMPHOPROLIFERATIVE-DISEASES IN HIV-SEROPOSITIVE PATIENTS -A STUDY OF 40 CASES AT A SINGLE INSTITUTION IN SPAIN
Authors: RIBAS A BELLMUNT J ALBANELL J CAPDEVILA JA OCANA I GALLEGO OS MALDONADO J GIRALT J SOLE LA
Citation: A. Ribas et al., MALIGNANT LYMPHOPROLIFERATIVE-DISEASES IN HIV-SEROPOSITIVE PATIENTS -A STUDY OF 40 CASES AT A SINGLE INSTITUTION IN SPAIN, Acta oncologica, 34(1), 1995, pp. 75-82
CORTICOID TREATMENT IN CASTLEMANS DISEASE
Authors: RIBAS A BELLMUNT J SOLE LA RIBASMUNDO M
Citation: A. Ribas et al., CORTICOID TREATMENT IN CASTLEMANS DISEASE, Medicina Clinica, 105(16), 1995, pp. 638-639
PHASE-II TRIAL OF AN ALL-ORAL REGIMEN OF TEGAFUR AND FOLINIC ACID IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER
Authors: SOLE LA ALBANELL J BELLMUNT J RIBAS A GALLEGO OS CARULLA J
Citation: La. Sole et al., PHASE-II TRIAL OF AN ALL-ORAL REGIMEN OF TEGAFUR AND FOLINIC ACID IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER, Cancer, 75(3), 1995, pp. 831-835
LATE RECURRENT METASTASIS IN WILMS-TUMOR
Authors: GALLEGOMELCON S DETOLEDO JS DOSTE D LOPEZ D MORAGA F RODRIGUEZ C VIDAL T BELLMUNT J
Citation: S. Gallegomelcon et al., LATE RECURRENT METASTASIS IN WILMS-TUMOR, Medical and pediatric oncology, 23(2), 1994, pp. 158-161
GENIC THERAPY - NEW PERSPECTIVES IN THE T REATMENT OF CANCER
Authors: RIBAS A BELLMUNT J
Citation: A. Ribas et J. Bellmunt, GENIC THERAPY - NEW PERSPECTIVES IN THE T REATMENT OF CANCER, Medicina Clinica, 103(20), 1994, pp. 776-779
BILATERAL CHOROIDEAL METASTASIS AS A FORM OF PRESENTATION OF PULMONARY-CARCINOMA
Authors: VILA A BELLMUNT J RILO A SABALLS P
Citation: A. Vila et al., BILATERAL CHOROIDEAL METASTASIS AS A FORM OF PRESENTATION OF PULMONARY-CARCINOMA, Medicina Clinica, 102(5), 1994, pp. 196-197
Risultati: 1-25 | 26-28